UNAUDITED FINANCIAL RESULTS FOR Q1 FY 26

Revenue Growth 20pctPat Growth 25pctExceptional ItemResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.9%Reaction day

₹111.80

prior close

₹109.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.4%-4.5% vs market

Specialty Chemicals peers, median of 83sector-0.3%-4.6% vs sector

On the reaction day the stock moved 4.5 pts less than Nifty Microcap 250 and 4.6 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.9

10m

+3.2

15m

+3.6

30m

+1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.9-0.4-4.5-0.3-4.6

Next day

-7.5-1.4-6.1-2.3-5.2

-5.6-1.7-3.8-2.3-3.3

-7.9-2.6-5.3-3.6-4.2

-8.6-2.4-6.2-4.2-4.4

-10.1-2.4-7.7-3.8-6.3

-7.7-2.5-5.2-3.4-4.3

15d

-10.5-2.7-7.8-3.9-6.6

-10.2-0.5-9.6-3.2-7.0

-12.3-1.0-11.3-4.9-7.4

-18.6-1.0-17.6-6.5-12.1

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 83Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Resonance Specialties reported a strong Q1 FY26 with revenue from operations rising about 23% year-on-year to Rs. 2,127.42 lakh from Rs. 1,730.22 lakh in Q1 FY25. Profit after tax jumped sharply to Rs. 163.04 lakh from Rs. 58.80 lakh a year earlier, an increase of roughly 177%. Basic EPS improved to Rs. 1.41 from Rs. 0.51. However, on a sequential basis, both revenue and profit came down compared to the strong Q4 FY25 quarter, suggesting some normalisation after a peak quarter. The auditor (Kailash Chand Jain & Co.) issued a clean limited review report with no qualifications. The company continues to operate in a single segment (chemical manufacturing) with no subsidiaries or joint ventures.

Likely market impact

The robust YoY growth in both revenue and profits signals healthy business momentum, which is positive for shareholders. The QoQ dip from a strong Q4 is not alarming and reflects normal quarter-to-quarter variation rather than weakness.